832-497-2220 [email protected]

Top-tier Chinese Pharmaceutical company profile: Luye Pharma Group

 Luye Pharma Group


  • 2019 Revenue: US$ 0.96 Billion
  • Number of Employees: 4,716
  • Founded: 1994


Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company focusing on drugs targeting the central nervous system (CNS), oncology, and other therapeutic areas. The company’s three main strategic priorities are global R&D, manufacturing, and the sale of innovative medications.

Overseas investment and collaboration

In 2019

– Collaborated with AstraZeneca to promote Xuezhikang capsules in global markets

– Licensed by PharmaMar to develop Lurbinectedin in China

In 2018,  

– Acquired AstraZeneca’s CNS products, Seroquel and Seroquel XR in 51 countries and regions

– Acquired the global rights to Bayer’s contraceptive patch product Apleek


The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 40 drug candidates in China and more than 10 drug candidates overseas. Along with a number of new drugs and new formulations to treat central nervous system diseases and oncology therapeutic areas. With an understudy in the U.S., Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others.

Products and Market

Luye Pharma is developing a global supply chain of 7 manufacturing sites with over 30 production lines, thus establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular system, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets – China, the U.S., Europe and Japan, as well as in fast-growing emerging markets.

Other projects


Submit a Comment

Your email address will not be published.